Radioligand Therapy: Actinium-225 Supply and Treatment Capacity Build-Out | Oncology Modality Intelligence

Description

List of Tables

Radioligand therapy's first commercial wave in Japan runs on lutetium-177: Pluvicto arrived in 2025, certified treatment sites are being built out, and the referral pathways are still forming. The second wave runs on actinium-225 - and the second wave has a supply problem. Alpha emitters deliver their energy over cell diameters rather than millimeters, and the early clinical experience with Ac-225 conjugates in prostate cancer and neuroendocrine tumors has made the isotope the most sought-after raw material in nuclear medicine. It is also one of the scarcest: production routes are few, global capacity is measured in quantities that force rationing across clinical programs, and every sponsor with an alpha program - Novartis with AAA817, AstraZeneca with the Fusion-acquired FPI-2265, Bristol Myers Squibb with RayzeBio's RYZ101, Bayer, Lilly, Telix, Full-Life - is competing for the same atoms. The contested questions sit at the intersection of physics and industrial policy. Which production route scales: thorium-229 generators, spallation, or reactor-based approaches, and who controls them - Orano Med and PanTera in Europe, NorthStar in the US, and which options does Japan itself have? How fast can Japan certify alpha-capable treatment sites, where handling requirements exceed those of the Lu-177 wave? And can Japanese radiopharma capability - anchored by PeptiDream's PDRadiopharma and its discovery partnerships - convert isotope scarcity into an industry position rather than a dependency? This report maps the entire chain: Ac-225 production technologies and their capacity economics, the supplier landscape and allocation dynamics, the sponsor pipeline by program and trial, Japan's site-certification trajectory after Pluvicto, domestic isotope-production options including accelerator and research-reactor routes, and the policy instruments that could anchor a Japanese supply position. It serves radiopharma companies and isotope suppliers, hospital operators planning nuclear-medicine investment, Japanese industrials evaluating entry, and investors trying to price the most constrained input in oncology's fastest-growing modality.

Scope and Coverage

The report covers Ac-225 production routes and suppliers, the alpha-emitter clinical pipeline, Japan's RLT site build-out and certification framework, domestic isotope-production options, and Japanese radiopharma discovery capability, with Lu-177 experience as the baseline.

Report Highlights

Ac-225 production technologies: Th-229 generators, spallation, and reactor routes compared
Supplier landscape: Orano Med, PanTera, NorthStar, and the allocation contest among sponsors
Alpha pipeline map: AAA817, FPI-2265, RYZ101, BAY 3563254, 225Ac-FL-020, and Pb-212 programs
Japan's RLT site-certification trajectory after the Pluvicto launch (2025)
Domestic Japanese isotope-production options: accelerator and research-reactor pathways
PeptiDream/PDRadiopharma and Japan's discovery-side position in radiopharma

Product Code: JPH-106

Table of Content

1. Executive Summary

2. Radioligand Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Novartis (CH) - Pluvicto and Lutathera; AAA817 (225Ac-PSMA-617) in Phase 3; Pluvicto Japan approval 2025 and Sasayama facility expansion
Eli Lilly (US) - POINT Biopharma acquisition (2023); Lu-177 and alpha-emitter pipeline
AstraZeneca (UK) - Fusion Pharma acquisition (Mar 2024); FPI-2265 (225Ac-PSMA-I&T) pivotal program
Bristol Myers Squibb (US) - RayzeBio acquisition (Dec 2023); RYZ101 (225Ac-DOTATATE) ACTION-1 program
ITM Isotope Technologies (DE) - n.c.a. Lu-177 supply; 177Lu-edotreotide and isotope production
Telix (AU) - Illuccix Japan application under review; Ac-225 and Lu-177 pipeline
Bayer (DE) - 225Ac-PSMA-Trillium (BAY 3563254) early program and the Xofigo legacy
Perspective Therapeutics (US) - Pb-212 alpha platform with VMT01 and VMT-alpha-NET
Full-Life Technologies (CN) - 225Ac-FL-020 PSMA program within a China radiopharma build-out
Orano Med (FR) - Pb-212 supply and the RadioMedix partnership (AlphaMedix)
NorthStar Medical Radioisotopes (US) - Ac-225 production scale-up
PanTera (BE) - SCK CEN/IBA joint venture for Ac-225 supply
Curium (FR) - Lu-177 PSMA-I&T production investment at Saclay and a nuclear-medicine network
PeptiDream (JP) - PDRadiopharma subsidiary; discovery partnerships including RayzeBio/BMS

Product Code: JPH-106

List of Tables

Table 1. Radioligand therapy primer: targeting, isotopes, and the alpha-versus-beta distinction
Table 2. Pluvicto Japan launch (2025): approval scope and initial site network
Table 3. Lutetium-177 supply chain as the baseline for alpha planning
Table 4. Ac-225 decay-chain physics and its clinical rationale
Table 5. Ac-225 production via thorium-229 generators: process and capacity characteristics
Table 6. Ac-225 production via spallation: the NorthStar approach
Table 7. Reactor-based and alternative Ac-225 production routes under development
Table 8. PanTera: the SCK CEN/IBA joint venture and its supply model
Table 9. Orano Med Pb-212 platform and the RadioMedix AlphaMedix partnership
Table 10. Perspective Therapeutics Pb-212 programs: VMT01 and VMT-alpha-NET
Table 11. Novartis AAA817 (225Ac-PSMA-617): Phase 3 program design
Table 12. AstraZeneca FPI-2265 (225Ac-PSMA-I&T): the Fusion acquisition (2024) and pivotal plan
Table 13. Bristol Myers Squibb RYZ101 (225Ac-DOTATATE): the RayzeBio acquisition (2023) and ACTION-1
Table 14. Lilly radiopharma build-out via the POINT Biopharma acquisition (2023)
Table 15. Bayer BAY 3563254 (225Ac-PSMA-Trillium) and the Xofigo legacy
Table 16. Telix alpha pipeline and the Illuccix Japan application under review
Table 17. Full-Life Technologies 225Ac-FL-020 and the China radiopharma build-out
Table 18. Curium Lu-177 production investment at Saclay and its nuclear-medicine network
Table 19. ITM isotope supply position and the 177Lu-edotreotide program
Table 20. PeptiDream PDRadiopharma: discovery platform and partnerships including RayzeBio/BMS
Table 21. Peptide, small-molecule, and antibody targeting vectors for alpha conjugates
Table 22. PSMA target competition across Lu-177 and Ac-225 programs
Table 23. Neuroendocrine tumor alpha programs: SSTR-directed pipelines
Table 24. Emerging alpha targets beyond PSMA and SSTR
Table 25. Renal and salivary toxicity management in alpha radioligand practice
Table 26. Combination strategies pairing alpha emitters with ARPI and chemotherapy
Table 27. Earlier-line development logic: pre-chemotherapy and hormone-sensitive settings
Table 28. Japan RLT site-certification framework after the Pluvicto launch
Table 29. Radiation-handling requirements for alpha emitters in Japanese facilities
Table 30. Japan's certified-bed build-out trajectory for radioligand therapy
Table 31. Referral-flow formation between urology, oncology, and nuclear medicine in Japan
Table 32. Domestic accelerator-based isotope-production options in Japan
Table 33. Japanese research-reactor resources relevant to medical isotopes
Table 34. Import-dependency structure of Japan's medical isotope supply
Table 35. Policy instruments supporting domestic isotope and radiopharma capacity
Table 36. NHI pricing framework for radioligand products in Japan
Table 37. PMDA review considerations for alpha-emitter products
Table 38. Isotope allocation mechanics: how sponsors secure Ac-225 supply
Table 39. Deal and partnership activity in alpha radiopharma, 2023-2026
Table 40. Competitive-position matrix of alpha-emitter programs
Table 41. Scenario grid for Ac-225 supply expansion by production route
Table 42. Scenario grid for Japan site-capacity growth through 2030
Table 43. Scenario grid for a Japanese domestic isotope position
Table 44. Risk register for alpha-program sponsors dependent on isotope supply
Table 45. Risk register for Japanese hospitals investing in RLT capability
Table 46. Key opinion leader and society landscape in Japanese nuclear medicine
Table 47. Workforce requirements: radiopharmacists, physicists, and certified physicians
Table 48. Watchlist of alpha-program readouts and supply events, 2026-2028
Table 49. Stakeholder map: isotope producers, sponsors, hospitals, regulators, and policymakers
Table 50. Timeline of alpha radioligand development and Japan RLT milestones, 2021-2026

List of Figures

Figure 1. Radioligand therapy mechanism schematic
Figure 2. Alpha-versus-beta emission physics and clinical implications
Figure 3. Pluvicto Japan launch map: sites and referral flows
Figure 4. Lu-177 supply chain as the alpha-planning baseline
Figure 5. Ac-225 production-route map: generators, spallation, and reactors
Figure 6. Th-229 generator production process flow
Figure 7. Spallation-based production: the NorthStar model
Figure 8. PanTera joint-venture supply architecture
Figure 9. Orano Med Pb-212 platform and partnership map
Figure 10. Perspective Therapeutics Pb-212 program structure
Figure 11. Novartis alpha pipeline anchored by AAA817
Figure 12. AstraZeneca-Fusion transaction and the FPI-2265 program (2024)
Figure 13. BMS-RayzeBio transaction and the ACTION-1 program (2023)
Figure 14. Lilly radiopharma build-out via POINT (2023)
Figure 15. Bayer alpha program and the Xofigo legacy
Figure 16. Telix pipeline and the Illuccix Japan pathway
Figure 17. Full-Life and the China radiopharma build-out
Figure 18. Curium and ITM supply positions in the Lu-177 chain
Figure 19. PeptiDream PDRadiopharma discovery-platform map
Figure 20. Targeting-vector taxonomy for alpha conjugates
Figure 21. PSMA competition map across Lu-177 and Ac-225 programs
Figure 22. Neuroendocrine alpha pipeline map
Figure 23. Emerging alpha target landscape
Figure 24. Toxicity-management framework for alpha radioligands
Figure 25. Combination strategies for alpha emitters
Figure 26. Earlier-line development logic for radioligand therapy
Figure 27. Japan RLT site-certification process map
Figure 28. Alpha-handling facility requirements in Japan
Figure 29. Certified-bed build-out trajectory framework
Figure 30. Referral-flow map among urology, oncology, and nuclear medicine
Figure 31. Domestic accelerator production options for Japan
Figure 32. Japanese research-reactor resources for medical isotopes
Figure 33. Import-dependency map of Japan's isotope supply
Figure 34. Policy-instrument map for domestic radiopharma capacity
Figure 35. NHI pricing framework for radioligand products
Figure 36. PMDA review pathway for alpha-emitter products
Figure 37. Isotope-allocation mechanics across sponsor programs
Figure 38. Alpha radiopharma deal map, 2023-2026
Figure 39. Competitive-position matrix of alpha programs
Figure 40. Ac-225 supply-expansion scenario tree
Figure 41. Japan site-capacity scenario tree through 2030
Figure 42. Japanese domestic isotope-position scenario tree
Figure 43. Risk map for isotope-dependent sponsors
Figure 44. Risk map for Japanese hospitals investing in RLT
Figure 45. Japanese nuclear-medicine KOL and society landscape
Figure 46. Radiopharma workforce pipeline in Japan
Figure 47. Alpha readout and supply event calendar, 2026-2028
Figure 48. Stakeholder map across the isotope-to-patient chain
Figure 49. Key-question tree for radiopharma investors and entrants
Figure 50. Alpha radioligand and Japan RLT milestone timeline, 2021-2026

Radioligand Therapy: Actinium-225 Supply and Treatment Capacity Build-Out | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Radioligand Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures